Influence of methylprednisolone on the reversal time of sugammadex: a randomized clinical trial
REVISTA BRASILEIRA DE ANESTESIOLOGIA, vol.70, no.2, pp.111-117, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 70 Issue: 2
- Publication Date: 2020
- Doi Number: 10.1016/j.bjan.2020.01.002
- Journal Name: REVISTA BRASILEIRA DE ANESTESIOLOGIA
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
- Page Numbers: pp.111-117
- Keywords: Sugammadex, Rocuronium, TOF, Methytprednisolone, Recovery, RESIDUAL NEUROMUSCULAR BLOCKADE, POSTEXTUBATION LARYNGEAL EDEMA, BLOCKING-AGENTS, DEXAMETHASONE, PREVENTION, MANAGEMENT
- Ankara University Affiliated: Yes
Abstract
Background and objectives: Sugammadex is a modified gamma-cyclodextrin that reverses the effects of aminosteroidal neuromuscular blocking agents. Likewise, some steroid molecules, such as toremifene, fusidic acid, and flucloxacillin, can also be encapsulated by sugammadex. Methylprednisolone, which is a synthetic steroid used commonly for airway oedema prophylaxis, can also be encapsulated by sugammadex. The objective of this study was to compare the recovery times of sugammadex for reversing rocuronium-induced moderate neuromuscular blockade in those who received intraoperative 1 nng.kg(-1) methylprednisolone or saline.